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1. Introduction 
To date there are 9 known neurological diseases caused by an expanded polyglutamine 
(polyQ) repeat, with the most prevalent being Huntington’s Disease (HD) (Cummings & 
Zoghbi, 2000). HD is a progressive autosomal dominant disorder. It is caused by a CAG 
repeat expansion in the HTT gene, which results in an expansion of a polyQ stretch at the N-
terminal end of the huntingtin (htt) protein. This polyQ expansion plays a central role in the 
disease and results in the accumulation of cytoplasmic and nuclear aggregates. In this 
chapter we will discuss wild-type htt function and the gain of toxic function of mutant htt in 
HD. Currently no treatment is available to delay onset or slow disease progression. 
However, recently developed RNA modulating therapies have great potential to lower 
mutant htt levels in HD. Already promising results in animal and human studies for other 
neurodegenerative disorders have been obtained, from which HD research can learn.  
2. Huntington’s Disease 
HD is an autosomal dominantly inherited neurodegenerative disorder. HD is rare, but more 
common in Western countries. The prevalence of HD in America is approximately 5 in 
100,000 (Shoulson & Young, 2011) and in Europe, the prevalence of HD may be even higher 
with estimates in England and Wales as high as 12 in 100,000 individuals (Rawlins, 2010).  
Post-mortem studies show that there is a 10-20 percent weight reduction in HD brains 
(Vonsattel et al., 1985). Neurodegeneration occurs throughout the forebrain with the 
GABAergic medium spiny neurons of the striatum as its first prominent victim, and to a 
lesser extent neurons in the cerebral cortex (Levesque et al., 2003). Severe cell loss in the 
striatal complex, the caudate nucleus and putamen results in striatal atrophy. This is 
accompanied by an enlargement of the lateral ventricles. The medium spiny projection 
neurons, containing enkephalin, are more susceptive to degeneration than substance P 
containing neurons while interneurons seem to be spared (Walker, 2007). With disease 
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progression, degeneration expands throughout the HD brain and other structures become 
affected (Vonsattel et al., 1985). Cortical atrophy is characterized by thinning of the cerebral 
cortex and the underlying white matter. Neuronal loss is abundant in cortical layers III, V 
and VI (Rosas et al., 2008) but is also prominent in the CA1 region of the hippocampus, with 
a reduction of about 9 percent (Rosas et al., 2003). 
Disease onset usually occurs around midlife and is clinically characterized by a combination 
of symptoms: cognitive impairments, movement abnormalities, and emotional disturbances. 
Motor symptoms of HD include chorea and occasionally bradykinesia and dystonia (Tabrizi 
et al., 2009). Choreic movements, recognized as involuntary and unwanted movements, start 
in the distal extremities. During the course of HD these movements become more profound 
and eventually all other muscles of the body are affected. These symptoms can initially 
appear as lack of concentration or nervousness and unsteady gait (Kremer et al., 1992). 
Psychiatric symptoms often precede the onset of motor symptoms. Irritability is commonly 
one of the first signs and occurs throughout the course of the disease. Other psychiatric 
symptoms involve anxiety, obsessive and compulsive behavior while apathy and psychosis 
can appear in advanced stages. However, the most frequent psychiatric symptom is 
depression (Craufurd et al., 2001). Like psychiatric symptoms, cognitive symptoms can be 
present prior to the onset of the motor symptoms. The cognitive symptoms comprise mainly 
impairment in executive functions, including abstract thinking, problem solving, and 
attention (Snowden et al., 2002). Furthermore, the ability to learn new skills is affected 
(Paulsen et al., 2001). Altogether these symptoms substantially impede social and 
professional functioning. Eventually patients are incapable to adequately perform daily 
activities finally leading to progressive disability, requiring full-time care, followed by death 
(Simpson, 2007). Death generally occurs 15 to 20 years post diagnosis due to complications 
such as pneumonia, falls, dysphagia, heart disease or suicide. 
The disease is caused by a CAG trinucleotide repeat expansion within the coding region 
of the HTT gene. The HTT gene was the first autosomal disease locus to be mapped by 
genetic linkage analysis in 1983 (Gusella et al., 1983) on the short arm of chromosome 4 
(4p16.3). The huntingtin protein (htt) was found to be ubiquitously expressed throughout 
the body, with highest expression in testis and brain (Strong et al., 1993), however, cells in 
the brain are specifically vulnerable to the toxic function of mutant htt. The CAG repeat 
expansion in the HTT gene results in an expanded polyQ repeat in the htt protein (The 
Huntington's Disease Collaborative Research Group, 1993). When the number of CAG 
repeats exceeds 39, the gene encodes a mutated form of the htt protein that is prone to 
aggregation. Alleles ranging 36 to 39 repeats, lead to an incomplete and variable 
penetrance of the disease or to a very late onset (McNeil et al., 1997). Repeat numbers 
exceeding 55-60 result in clinical manifestation of the disease before the age of 20, known 
as Juvenile Huntington’s Disease (JHD) (Andresen et al., 2007) and both sexes are affected 
with the same frequency (Walker, 2007). Intergenerational CAG changes are extremely 
rare on normal chromosomes but on expanded chromosomes changes in CAG size take 
place in approximately 70 percent of meioses and expansion is more likely via the 
paternal line (Kremer et al., 1995).  
There is a strong inverse correlation between repeat numbers and the age of onset of the 
disease. The repeat length accounts for approximately 70 percent of the variance in age of 
onset (Roos, 2010). However, no correlation with repeat size is apparent for the progression 
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and duration of the disease. Furthermore, neuropathological changes, such as atrophy and 
inclusion load are clearly correlated with the CAG repeat number.  
For patients, only symptomatic treatment is available and a treatment to slow down the 
progression or delay the onset of the disease remains elusive. 
2.1 Huntingtin protein  
When the HTT gene was discovered in 1993, the htt protein had an unknown function. Since 
then, enormous research efforts have revealed many functions of the wild-type protein 
(discussed in the present paragraph) and many toxic gain of functions of the mutant protein 
(discussed in the next paragraph).  
Wild-type htt is mainly localized in the cytoplasm, although a small proportion is present in 
the nucleus (de Rooij et al., 1996; Kegel et al., 2002). The protein is known to be associated 
with microtubules, the plasma membrane, Golgi complex, the endoplasmic reticulum, and 
mitochondria. Furthermore htt is associated with vesicular structures, such as clathrin-
coated and non-coated vesicles, autophagic vesicles, endosomal compartments or caveolae 
(Kegel et al., 2005; Strehlow et al., 2007; Rockabrand et al., 2007; Atwal et al., 2007; Caviston 
et al., 2011). 
Three of the first 17 amino acids at the amino terminus of htt are lysines, which are targets 
for post translational modifications that regulate htt half-life and are proposed to be 
involved in targeting htt to various intracellular membrane-associated organelles (Kalchman 
et al., 1996; Steffan et al., 2004; Kegel et al., 2005; Atwal et al., 2007; Rockabrand et al., 2007). 
The first 17 amino acids of htt have also been suggested to act as nuclear export signal (NES) 
by interaction with the nuclear pore protein translocated promoter region (Tpr) that then 
transports N-terminal htt fragments out of the nucleus (Cornett et al., 2005). The polyQ 
repeat starts at the 18th amino acid and is thought to form a polar zipper structure, which 
has been implicated in the interaction between different polyQ-containing transcription 
factors (Perutz et al., 1994; Harjes & Wanker, 2003). The polyQ stretch is followed by a 
polyproline repeat, which is thought to be involved in keeping the protein soluble (Steffan et 
al., 2004). Additionally, three main HEAT (htt, elongation factor 3, protein phosphatase 2A, 
and the yeast PI3-kinase TOR1) repeat motifs are identified which are known to form 
superhelical structures and are involved in protein-protein interactions (Takano & Gusella, 
2002; Li et al., 2006). Htt is palmitoylated at the cysteine residue 214 by htt interacting 
protein (Hip) 14, which is thought to be involved in htt trafficking (Huang et al., 2004). Htt 
has various proteolytic cleavage motifs, with a hotspot between amino acid 500 and 600, 
which are recognized by various proteases, such as caspases 1, 3, 6, 7 and 8 and calpain 
(Gafni & Ellerby, 2002; Wellington et al., 2002; Kim et al., 2006). In contrast to mutant htt, the 
significance of wild-type htt cleavage is not completely clear. 
2.2 Mutant htt gain of toxic function in HD 
Expanded polyQ proteins are known to undergo conformational changes, which result in 
the hallmark of polyQ disorders, protein aggregates. The aggregates can already be found 
before the onset of the first symptoms (Weiss et al., 2008). Remarkably, there is growing 
evidence suggesting that these aggregates are not good indicators for disease onset and 
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progression (Wanker, 2000; van Roon-Mom et al., 2006). The rate of aggregate formation is 
correlated to the length of the polyQ repeat (Legleiter et al., 2010). Whether accumulation of 
these aggregates is neurotoxic or neuroprotective is still under debate since evidence also 
suggests that soluble mutant htt is the main toxic component (Davies et al., 1997; Saudou et 
al., 1998; Arrasate et al., 2004). While the expanded polyQ repeat displays pathogenic 
properties it is probably not essential for normal function (Clabough & Zeitlin, 2006). 
Mutant htt is more disposed to proteolysis and it was shown that small N-terminal htt 
fragments are more toxic than full length mutant htt (Cooper et al., 1998). Proteolytic 
cleavage of mutant htt results in nuclear localization of toxic N-terminal mutant htt 
fragments. These N-terminal mutant htt fragments are important in the pathological 
process. Mutant htt fragments within the striatum of HD brains clearly differ from those of 
control brains, suggesting cleavage is disease specific (Mende-Mueller et al., 2001) and htt 
caspase-6 resistant HD mice did not show neuronal dysfunction (Graham et al., 2006). 
Various transcription factors have been found to co-localize with htt aggregates, such as 
TATA box binding protein (TBP), CREB binding protein (CBP) and p53 (Steffan et al., 2000; 
van Roon-Mom et al., 2002). These co-aggregated proteins can no longer assert their normal 
function and could thereby contribute to HD pathology (Nucifora, Jr. et al., 2001) 
Mutant htt is also suggested to act as pro-apoptotic factor triggering cell death. Htt is found 
to bind to the pro-apoptotic factor p53. Interestingly, p53 deficient HD mice displayed 
increased striatal inclusion body formation (Ryan et al., 2006). Expression of mutant htt in 
p53 deficient mice improved the lifespan probably by increased apoptosis initiated by 
mutant htt (Ryan & Scrable, 2008). 
In HD the fusion machinery and axonal transport are impaired. Accumulated N-terminal 
fragments block the axonal machinery, resulting in transport defects (Gunawardena et al., 
2003). Endocytosis is thought to be impaired since the synaptic vesicle protein PACSIN1 has 
an altered subcellular location in early stage HD patients (Modregger et al., 2002). Finally, 
various proteins involved in exocytosis are known to have decreased expression levels in 
HD patients. Proteins involved in docking and fusion of vesicles show reduced transcript 
expression, suggesting a defect in the neurotransmitter release machinery in HD patients 
(Smith et al., 2007).  
N-terminal mutant htt fragments are found to be associated with the surface of 
mitochondria in transgenic and knock-in HD mice (Panov et al., 2002; Orr et al., 2008). The 
accumulation of mutant htt on mitochondria is increasing with age and correlates with 
disease progression. This impaired mitochondrial trafficking by N-terminal mutant htt 
could lead to decreased ATP supply in nerve terminals (Orr et al., 2008). Mutant htt is also 
suggested to be involved mitochondrial energy metabolism defects. Metabolic energy 
defects could be the result of mutant htt’s capability to induce mitochondrial permeability 
transition pore opening. This leads to low mitochondrial membrane potential and high 
glutamate transmission, resulting in overactive glutamate NMDA receptors (excitotoxicity) 
(Choo et al., 2004). Abnormal mitochondrial respiratory chain function leads to reduced 
ATP levels and subsequent partially depolarized membrane. This voltage change leads to 
chronic calcium influx and activation of proteases, causing more reactive oxygen species 
(ROS) production. Further, increased ROS production gives rise to oxidative stress and 
could contribute to the vicious circle (Browne & Beal, 2006).  
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2.3 Loss of wild-type function in HD 
As described above, the main cause of HD is a gain of toxic mutant htt function. Since 
various functions and post-translational modifications of htt are altered in HD, loss of wild-
type htt function could also be involved. Htt expression is important for normal cellular 
function since knock-out of the homologous htt mouse gene was found to be early 
embryonic lethal (Zeitlin et al., 1995). Previous studies have shown that approximately 50% 
of htt protein level is required to maintain cell functionality (Dragatsis et al., 2000). Next to 
embryonic development, htt is also involved in regulation of apoptosis, transcription, 
intracellular transport and BDNF transcription (Zuccato et al., 2001; Imarisio et al., 2008).  
Wild-type htt is reported to act as protector of the brain cells from apoptotic stimuli 
(Rigamonti et al., 2000). Reduced wild-type htt expression in transgenic HD mice resulted in 
worsening of the behavioural deficits and survival. In addition, no severe striatal 
abnormalities were visible in those HD mice, which could mean that the striatal phenotype 
is mainly caused by mutant htt toxicity (Zhang et al., 2003). Furthermore, overexpression of 
wild-type htt protected these mice against neurodegeneration. Removal of endogenous htt 
in a Drosophila melanogaster (D. melanogaster) HD model was found to exacerbate the 
neurodegenerative phenotype associated, suggesting that loss of normal htt function might 
also contribute to HD pathogenesis (Zhang et al., 2009). 
3. HTT RNA  
Although the main toxic component is the htt protein, recent evidence suggests that also 
HTT RNA could have toxic properties. There is also recent evidence for antisense 
transcription through the HTT locus. In this paragraph we will review the importance of 
these findings. 
3.1 Htt RNA gain of function in HD 
Trinucleotide expansion disorders occur either in untranslated genomic regions (UTRs) 
resulting in a toxic RNA gain of function or loss of gene function, or in coding regions 
resulting in a gain of toxic protein function (Orr & Zoghbi, 2007). Until recently, it was 
believed that HD is solely caused by a toxic gain of function of the polyQ protein and to a 
lesser extent, loss of wild-type function. However, recent evidence suggests that the mutant 
CAG repeats of the HTT RNA transcript could also have toxic properties (Fig. 1). This RNA 
toxicity is caused by the long hairpin structures of the expanded RNA that result in 
abnormal interactions with double stranded RNA-binding proteins. 
The CAG repeat hairpin in the HTT transcript was found to be stabilized by the flanking 
(CCG)n repeat (de Mezer et al., 2011). The resulting double stranded CAG RNA hairpin 
formed intranuclear foci that co-localized with the muscleblind-like 1 (MBNL1) splicing 
factor (Jiang et al., 2004). Altered MBNL1 function is implicated in RNA toxicity of CUG 
repeat expansion disorders such as myotonic dystrophy type 1 (DM1) (Kanadia et al., 2003). 
DM1 is caused by a CTG repeat expansion at the 3’ UTR of the DMPK gene. The CTG 
repeats are known to form stable hairpin structures that are toxic by causing abnormal 
alternative splicing by MBNL1 binding and sequestering in nuclear foci (Fardaei et al., 2001; 
Kanadia et al., 2003). Similar to expanded CUG repeats in DM1, synthesized expanded CAG 
repeats also resulted in abnormal alternative splicing in both transiently transfected and 
www.intechopen.com
 
Huntington’s Disease — Core Concepts and Current Advances 
 
446 
patient-derived cells (Mykowska et al., 2011). The RNA toxicity modifier MBNL1 was also 
found to be involved in another polyQ disease, namely spinocerebellar ataxia 3 (SCA3). 
MBNL1 was found to be up-regulated in a D. melanogaster model of SCA3. The 
neurodegenerative disorder SCA3 is caused by a CAG repeat expansion in the ATXN3 gene, 
which results in the expression of a polyQ containing ataxin-3 protein. Upregulation of the 
D. melanogaster homolog of MBNL1 (mbl) was found to enhance pathogenic ataxin-3 protein 















PolyQ induced toxicity CAG repeat RNA toxicity
HTTAS
CUG
Increased mutant htt toxicity
 
Fig. 1. Schematic representation of modes of huntingtin toxicity in HD. Mutant htt 
transcription results in mutant HTT mRNA which can form double stranded hairpins 
through the expanded CAG repeat and adjacent CCG repeat. The CAG hairpin is involved 
in MBNL1 induced alternative splicing and toxicity. The main pathological process in HD 
involves the translation of expanded CAG repeat-containing mRNA into a toxic polyQ 
protein. Antisense transcription through the HTT gene results in a HTT antisense transcript 
(HTTAS). This HTTAS regulates HTT sense levels. In HD there is lower expression of 
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HD and SCA3 transgenes with a CAG repeat interrupted by CAA codons (expressing an 
identical polyQ protein as compared to a pure CAG repeat) showed only a mild phenotype, 
indicating the importance of the expanded pure CAG repeat for the toxic phenotype. 
Interestingly, both full CAG repeats and CAA interrupted CAG repeats showed similar 
levels of protein inclusions, indicating that the phenotype severity does not correlate with 
the number of inclusions (Li et al., 2008). 
Recently, transgenic mice expressing a GFP construct with 200 CAGs in the 3’ UTR resulted 
in reduced GFP levels as compared to animals with 23 CAG repeats in their 3’ UTR of the 
GFP construct (Hsu et al., 2011). Furthermore, these CAG200 mice showed nuclear RNA foci 
and a reduced breeding efficiency, which supports the gain of RNA toxicity hypothesis. 
Transgenic Caenorhabditis elegans (C. elegans) expressing various CAG repeat lengths in the 3’ 
UTR of a GFP gene showed a length-dependent toxicity. Worms with an 83 CAG repeat did 
not show any phenotype, whereas C. elegans expressing 200 CAGs died within a few days. 
Both 125 CUGs and 125 CAGs co-localized in nuclear foci with C. elegans MBNL1 homolog 
CeMBL and overexpression of CeMBL partly reversed the CAG 125 induced phenotype 
(Wang et al., 2011).  
In contrast to the above studies, there is also evidence that the CAG repeat RNA is not toxic. 
Expression of a cDNA construct with 79 CAG repeats in the 3’ UTR did not induce cell 
death, whereas a construct expressing 79 CAGs in the coding region did induce cell death 
(Ikeda et al., 1996). This was also found in two other polyQ disorders, spinocerebellar ataxia 
1 (SCA1) and spinobulbar muscular atrophy (SBMA). A SCA1 mouse model with impaired 
nuclear localization signal in ataxin-1 did not show nuclear inclusion bodies and did not 
display the disease phenotype (Klement et al., 1998). Furthermore, impairing nuclear 
localization of the androgen receptor (AR) in SBMA by castration showed marked 
improvements of disease pathology, also suggesting that the pathology is mainly caused by 
gain of toxic protein and not RNA (Katsuno et al., 2002). A D. melanogaster model of CAG 
toxicity expressing a repeat construct with a premature termination codon before a 93 CAG 
repeat, did not show any phenotype (McLeod et al., 2005). Based on these results, it was 
suggested that the toxicity in CAG triplet repeat disorders was exclusively the result of 
expanded polyQ protein gain of function. 
From the above we can conclude that not only gain of toxicity by expanded polyQ protein, 
but also RNA toxicity from the expanded CAG repeat could be involved in HD pathology. 
However, the size of the CAG repeat is critical for RNA pathogenicity.  
3.2 HTT antisense transcription 
A large proportion of the genome can produce transcripts from both strands (Katayama et al., 
2005). It has become clear that antisense transcripts are involved in triplet repeat disorders and 
bidirectional transcription has thus far been identified in DM1, spinocerebellar ataxia 8 (SCA8), 
and HD like 2 (HDL2) (Moseley et al., 2006; Wilburn et al., 2011). 
In SCA8, which is caused by a CTG repeat expansion in a transcribed but not translated 
ATXN8OS gene, it was thought that the expanded CTG repeat caused RNA toxicity (Koob et 
al., 1999). Unexpectedly, bacterial artificial chromosome (BAC) transgenic SCA8 mice 
showed 1C2 positive inclusion bodies. The 1C2 antibody specifically recognizes expanded 
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polyQ tracts, which are the hallmark of polyQ disorders. A novel transcript called ataxin-8, 
which encodes a polyQ protein, was expressed from the opposite strand, suggesting polyQ 
induced toxicity (Moseley et al., 2006). A BAC HDL2 mouse model with a pathogenic CTG 
repeat on the sense and expanded CAG repeat on the antisense strand at the Junctophilin-3 
locus showed both RNA toxicity caused by its expanded CUG repeat as well as protein 
toxicity by its polyQ translated expanded CAG repeat (Wilburn et al., 2011). These findings 
suggest that triplet repeat disorders can involve toxic gain of function of both protein and 
RNA by bidirectional transcription. 
Recently, two natural HTT antisense (HTTAS) transcripts were identified at the HD locus 
(Chung et al., 2011). HTTAS was found to be 5’ capped, poly A-tailed and contained 3 
exons. There were two different isoforms identified of which one enclosed a functional 
promotor and the CTG repeat. The HTTAS containing the short CTG repeat was found to be 
widely expressed in multiple tissues. Remarkably, expanded CTG repeat containing HTTAS 
was strongly reduced in HD brains. The authors state that HTTAS acts as a negative 
regulator for HTT transcript expression as knock-down of HTTAS resulted in higher htt 
levels and overexpression of HTTAS resulted in lower HTT levels (Chung et al., 2011). This 
negative regulating property on HTT of HTTAS could potentially have a clinical implication 
by overexpressing HTTAS in HD patients, thereby alleviating pathogenicity by lowering htt 
levels. 
4. RNA modulating therapies in HD  
Although the HTT gene was identified in 1993, there are no treatments to cure or even slow 
down the progression of the disease. Most therapeutic strategies under investigation are 
targeting one of the many altered cellular processes caused by toxic mutant htt. Targeting a 
single cellular process might be inadequate to be clinically beneficial.  
A more effective approach would be to reduce the expression of the causative HTT gene and 
thereby inhibiting all downstream toxic effects. Recent advances to inhibit the formation of 
mutant polyQ proteins using RNA modulating therapies, such as RNA interference (RNAi) 
and antisense oligonucleotides (AONs) look promising for HD (Sah & Aronin, 2011). RNAi 
is an endogenous cellular process involved in transcriptional regulation and acts as cellular 
defense mechanism against exogenous viral components. RNAi by introducing small 
interfering RNA (siRNA), short hairpin RNA (shRNA), or artificial micro RNA (miRNA), is 
increasingly used as a potential therapeutic tool to reduce expression of target transcripts. 
Specific knock-down is also achieved by introducing modified single stranded AONs that 
can hybridize to the target RNA, which is subsequently degraded or its translation blocked.  
The most frequently used htt RNA modulating strategies for HD are: Knock-down of total 
htt RNA levels by targeting both wild-type and mutant htt and allele-specific reduction of 
mutant htt RNA only (Fig. 2).  
4.1 Gene therapy to lower both htt alleles in HD 
Since htt has many important wild-type functions, one of the key questions that needs to be 
answered for htt lowering strategies to become successful is how much htt is needed for 
normal function, or rather, how much can htt levels be reduced before adverse effects 
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become apparent. Below we will first describe the studies describing lowering of both wild 
type and mutant htt, followed by the different approaches for allele specifically lowering 
mutant htt only. 
Various synthetic oligonucleotides with different modifications and backbones have been 
used in rodents to partially lower htt expression. A partial reduction of both normal and 
mutant htt by 25 to 35% using shRNAs was found to be well-tolerated in wild-type rats up 
to 9 months without signs of toxicity or striatal degeneration (Drouet et al., 2009). Total 
silencing using artificial miRNAs for both wild-type and mutant htt of 75% within the 
striatum of a transgenic HD mouse model showed reduced toxicity, extended survival, and 
improved motor performance, 3 months after treatment (Boudreau et al., 2009). 
Striatal injection of non allele-specific artificial miRNA in wild-type mice resulted in 70% 
reduction of htt levels. The high murine htt transcript reduction was sustained without 
adverse side effects up to the end of their study, which was set at 4 months (McBride et al., 
2008). Since htt lowering strategies will be most beneficial for patients when administered over 
many years, the long-term safety needs to be assessed. Therefore, simultaneously lowering 
transcript levels from both alleles can only be applied once the role of wild-type htt in the 
human brain is elucidated in more detail. Moreover, to date it is not known if there is equal 
transcription from both the mutant and wild-type htt allele. Lowering total htt transcript levels 
by 70% does not necessarily mean an equal reduction of both alleles by 70%. 
4.2 Allele-specific reduction of mutant htt in HD 
As described in previous paragraphs, endogenous htt expression is important for normal 
cellular function and an ideal strategy for an autosomal dominant disorder as HD would be 
to specifically target the mutant allele and thereby maintaining as much wild-type htt 
protein as possible. Suppression of 50% to 80% using siRNA specific for human mutant htt 
in transgenic rodent models of HD for 4 months was found to improve motor and 
neuropathological abnormalities and prolonged longevity in HD mice (Harper et al., 2005; 
Wang et al., 2005). These studies showed that lowering mutant htt without reducing wild-
type htt levels, resulted in an improved pathology. These results favored an allele-specific 
htt lowering approach without altering the expression of endogenous wild-type htt 
expression. Various studies have shown that a pronounced decrease of mutant htt levels, 
with only minor reductions in wild-type htt is feasible using allele-specific oligonucleotides. 
The different approaches, their advantages and disadvantages will be discussed in the 
following paragraph. 
4.2.1 Targeting associated SNPs in HD 
Single nucleotide polymorphisms (SNPs) are DNA sequence variations that occur when a 
single nucleotide is different between the two alleles of a gene. One way to distinguish 
between the wild-type and polyQ disease-causing allele is to target such a SNP that is unique 
to the mutant transcript using siRNAs (Miller et al., 2003). siRNAs are known to discriminate 
between transcripts that differ at a single nucleotide and various studies have shown specific 
reduction of mutant htt mRNA using siRNAs directed against different SNPs. The first 
evidence of allele-specific silencing in HD using using SNP specific RNAi was obtained in 
human cells overexpressing htt transgenes (Schwarz et al., 2006). The first prove of principle of 
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endogenous mutant htt silencing using SNPs in fibroblasts derived from HD patients was 
acquired in 2008 (van Bilsen et al., 2008). Extensive genotyping revealed a group of 22 SNPs 
highly associated with mutant htt alleles in a European HD cohort (Warby et al., 2009). Since 
then, various groups have shown that the vast majority of the HD patient population could be 
treated using 5 (75% of HD patients) or 7 (85% of the HD patients) different siRNAs (Lombardi 
et al., 2009; Pfister et al., 2009). The most promising SNP was found to be located in exon 67 of 
the HTT gene. This SNP is strongly associated with the mutant allele and 48% of the total 
Western HD population was heterozygous at this site (Pfister et al., 2009).  
Most of the heterozygous SNPs linked to the expanded CAG repeat in exon 1, are found 
remote downstream from the CAG repeat in exons 25 up to 67 (Lombardi et al., 2009; Pfister 
et al., 2009). To determine in HD patients whether they are heterozygous and if yes, which 
SNP belongs to the expanded CAG repeat, a technique called SNP linkage by circularization 
(SLiC) was developed (Liu et al., 2008). By circulating the DNA, the CAG repeat and SNP 
site were brought together, making it easy to link the SNP to the expanded CAG repeat 
using a single PCR. 
Although the selectivity obtained from above described SNP targeting siRNAs are very 
promising, there are some limitations. The diversity of SNPs within patient populations 
would make it necessary to develop multiple siRNAs. Furthermore, for HD patients that do 
not exhibit any of the most frequent SNPs a different treatment needs to be developed.  
4.2.2 Targeting the expanded CAG repeat in mutant HTT 
Another approach to achieve allele-specific silencing is based on the common denominator 
of all HD patients; their expanded CAG repeat. The selective silencing is either based on the 
hypothesis that there are structural differences between wild-type and mutant htt mRNA, or 
based on the larger number of CAGs in the expanded repeat and subsequent more binding 
possibilities. The first prove for allele discrimination by targeting the CAG repeat was 
achieved in HD human fibroblasts using a siRNA with 7 consecutive CUG nucleotides (Krol 
et al., 2007). Further studies with CAG repeat targeting siRNAs showed a low selectivity for 
the mutant allele, making siRNAs incompatible for CAG repeat directed allele-specific 
silencing (Hu et al., 2009). Other chemical modifications and oligomers show much higher 
specificity for expanded CAG repeat transcripts. Single stranded peptide nucleic acids 
(PNA), locked nucleic acids (LNA), and AONs with a 2’O methyl addition and 
phosphorothioate backbone targeting CAG repeats have been used to specifically reduce 
expanded HD transcripts in vitro in patient derived skin and blood cells (Hu et al., 2009; 
Evers et al., 2011). However, PNA selectivity was less pronounced in CAG repeat lengths 
(40 to 45 CAGs) that occur most frequently in the HD patient population. The allele-specific 
reduction after transfection of patient cells with LNAs and AONs with 7-mer CUG repeats 
was more pronounced in the average HD CAG repeat length. Furthermore, other 
endogenous CAG repeat containing transcripts with important cellular functions were 
unaffected by the tested CUG oligonucleotides (Hu et al., 2009; Evers et al., 2011). 
The main advantages of LNAs and AONs are that they are single stranded and do not show 
toxicity in vivo. Systemic delivery of modified AONs in Duchenne muscular dystrophy 
(DMD) boys carrying specific deletions in the DMD gene induced the synthesis of novel, 
internally deleted, but likely (semi-) functional, dystrophin proteins without clinically 
apparent adverse event (Goemans et al., 2011). 
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Fig. 2. RNA modulating therapeutic approaches for lowering htt. Two different HTT RNA 
modulating strategies used for HD are: A) Non allele-specific reduction of total HTT RNA 
levels by targeting a sequence that is identical in both the wild-type and mutant HTT 
transcript. B) Allele-specific reduction of mutant HTT RNA by targeting a unique 
heterozygous SNPs only present in the mutant transcript or C) Allele-specific reduction 
targeting the expanded CAG repeat on the mutant HTT transcripts. 
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Likewise, the use of only a single AON was suggested to be effective as treatment of various 
polyQ diseases (Hu et al., 2009; Evers et al., 2011). One expanded CAG repeat targeting 
AON was found to specifically reduce the expression of mutant ataxin-1 and ataxin-3 
mRNA levels in SCA1 and 3, respectively, and mutant atrophin-1 in dentatorubral-
pallidoluysian atrophy (DRPLA) in patient derived cells (Evers et al., 2011). 
Although these results are promising, extensive research is needed to elucidate the 
mechanism used by those oligonucleotides to induce selective silencing and to assess 
specificity and safety. Likewise, the full potency of this allele-specific treatment will be 
revealed when the first in vivo results are obtained.  
5. RNA modulating therapies in other neurodegenerative diseases 
AONs have also been used for the treatment of neurodegenerative disorders and are found 
to be taken up by neurons when delivered into the cerebral lateral ventricles. Here are some 
examples showing therapeutic benefit in animal models and/or clinical trials. 
5.1 Prevention of mutant protein translation 
We will first focus on the neurodegenerative disorder amyotrophic lateral sclerosis (ALS) 
where RNA modulating therapeutics are used to reduce transcript levels of disease causing 
protein. The RNA modulating therapeutics to treat ALS are currently tested in a phase I 
clinical trial. 
The progressive neurodegenerative muscle weakness disorder ALS is a caused by loss of 
motor neurons in the brain and spinal cord (Al-Chalabi & Leigh, 2000). The first mutations 
linked to the familial form of ALS (fALS) were found in the superoxide dismutase 1 (SOD1) 
gene. Mutated SOD1 is known to be toxic and prone to aggregation. Only approximately 1% 
of ALS cases is the result of mutations in the SOD1 enzyme (Bossy-Wetzel et al., 2004). 
RNA modulating therapies that have been used in ALS were designed to block the 
translation of SOD1. In a transgenic mouse model of ALS, 2’O methoxyethyl modified 
AONs were used to lower mutant SOD1 levels by binding and subsequent RNase H 
mediated breakdown of SOD1 transcripts. Continuous ventricular infusion of the SOD1 
targeting AON significantly slowed disease progression (Smith et al., 2006). The first results 
of a phase I study testing the safety of this SOD1 targeting AON in patients with fALS 
caused by mutant SOD1 are expected at the end of 2011. The outcomes of this phase I trial 
will be vital for future trials with RNA modulating therapies in HD. 
5.2 Modulating pre-mRNA splicing 
RNA modulating therapeutics are also used to modulate pre-mRNA splicing events in 
spinal muscular atrophy (SMA) using modified AON in vivo. 
SMA is an autosomal recessive neuromuscular disorder caused by loss of function of the 
survival motor neuron 1 (SMN1) gene. This homozygous deletion of SMN1 results in 
degeneration of motor neurons in the anterior horn of the spinal cord and lower brain stem 
(Bowers et al., 2011). Depletion of SMN1 is not embryonic lethal because of the presence of 
the almost identical SMN2 gene. However, due to a point mutation in an intron the SMN2 
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transcript is not correctly spliced. The majority of SMN2 transcripts are therefore lacking 
exon 7, which results in a truncated protein and lower expression of a functional SMN 
protein (Lorson et al., 2010).  
Current therapeutic strategies are aimed at modulating alternative splicing of SMN2. 
Transfecting fibroblasts with an AON blocking intronic splicing silencers in intron 7 of 
SMN2 were found to result in inclusion of SMN2 exon 7 (Singh et al., 2006). Injection of 
differently modified AONs into the brains of SMA mouse models resulted in increased exon 
7 inclusion and subsequent elevated SMN protein levels. The AON treated SMA mice 
displayed increased muscle size and extended survival (Williams et al., 2009; Hua et al., 
2010; Passini et al., 2011). 
Another modulating pre-mRNA splicing strategy involves the addition of a functional 
moiety to the AON to replace the missing splicing enhancer protein, thereby enhancing the 
inclusion of exon 7 by the splicing machinery (Cartegni & Krainer, 2003; Skordis et al., 2003). 
Several in vivo studies have shown increased SMN2 protein levels after intraventricular 
injection of splicing factors recruiting AONs (Dickson et al., 2008; Baughan et al., 2009). 
The AONs to treat SMA show promising results in vivo and the progression in therapeutics 
will be monitored closely. Results regarding delivery of the AON to the brain in humans 
and how well the AON is tolerated will be very useful for the development of RNA 
modulating therapeutics for HD. 
6. Drug delivery to the brain, how to cross the blood brain barrier? 
One major challenge of AON therapies for neurodegenerative disorders is delivery of the 
AON to the target organ. In the following paragraph we will describe in short the blood 
brain barrier function and how this impairs the uptake of peripherally administered drugs. 
We will focus in particular on the limitations and possibilities of AON delivery to the brain 
and will speculate on future clinical applications.  
6.1 Blood brain barrier 
A unique feature of the brain is that it is separated from the blood by the blood brain barrier 
(BBB). This is a monolayer of endothelial cells forming tight junctions through the 
interaction of cell adhesion molecules (Palmer, 2010). Astrocytes with their processes 
surrounding the endothelial cells, pericytes located between the endothelial cells and 
astrocytes, macrophages, and the basement membrane, form the other structural 
components of the BBB. Endothelial cells of the BBB are characterized by only few fenestrae 
and pinocytic vesicles, limiting transport to and from the brain. In this respect, it should be 
noted that the BBB also separates largely the immune system from the brain. Despite this 
gate-controlling system, essential nutrients, such as glucose, are permitted to pass (Bernacki 
et al., 2008). In neurodegenerative diseases, including HD, disruption of the BBB is common 
(Tomkins et al., 2007; Palmer, 2010). Interestingly, in animal models, this can even lead to 
neurodegenerative changes itself (Tomkins et al., 2007).  
The BBB has been already noticed in the work of Paul Ehrlich, Nobel Prize winning 
bacteriologist in the late 19th century. Injected dyes stained all organs except the brain and 
spinal cord. However, he did not attribute this phenomenon to the presence of a barrier but 
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to dye characteristics. His student showed later that staining of the brain was possible when 
the dye was injected directly into the brain (Palmer, 2010). Subsequent studies using electron 
microscopy were able to directly visualize the BBB.  
The BBB is a major challenge in central nervous system (CNS) drug development. When a 
drug is administered to the body, a fraction will be bound to proteins (e.g. serum 
albumin, lipoprotein etc.) and a fraction will be free. The free fraction is the 
pharmacologically relevant fraction, since it is available to cross the BBB (Palmer, 2010), 
depending on its physiochemical properties. After crossing the BBB, the drug will enter 
the interstitial fluid and go to the target (proteins, receptors, transporters etc.). 
Subsequently, the interstitial fluid drains to the cerebrospinal fluid (CSF), which is 
produced at a rate of 500 ml/day in humans, while the ventricle system can house only 
100-150 ml. This means that there is at least 3 times CSF circulation, allowing continuous 
drainage of the brain’s interstitial fluid.  
6.2 Crossing the blood brain barrier 
In the process of drug discovery, the aim is to find a substance which is potent, selective and 
preferably bioavailable. In addition, it needs to be able to cross the BBB, and reach the target 
at a sufficient concentration (Alavijeh et al., 2005). The following mechanisms are available 
to cross the BBB. The first one is simple diffusion. Small lipophilic substances which have a 
hydrogen bond are more likely to pass the BBB (Gerebtzoff & Seelig, 2006). The second 
mechanism is via active transport mediated by transporter molecules. The most well-known 
is glucose with its glucose transporter 1 (GLUT1), which is the most widely expressed 
among the GLUT family (13 isoforms) (Guo et al., 2005; Palmer, 2010). Other carriers are for 
instance lactate and amino acids. A well-known drug transported via this way is levodopa 
(Cotzias et al., 1967). The third mechanism to cross the BBB is via receptor-mediation. 
Receptor-mediated endocytosis allows macromolecules to enter the brain, such as 
transferrin, insulin, leptin, and insulin-like growth factor 1 (Pardridge, 2007).  
Besides systemic mechanisms to cross the BBB, there are also techniques to bypass the BBB 
by direct infusions into the subdural space, the brain’s ventricle system, or the brain 
parenchyma. These infusions can be single, repeated, or continuous depending on the 
methodology, using either simple or sophisticated pump systems. It is possible to use one 
probe or more probes for infusion. Using the subdural and ventricle compartments, diffuse 
delivery of the drug into the brain can be achieved, while using intraparenchymal delivery, 
a local, but well-targeted delivery can be realized 
When a substance has successfully entered the brain, there are mechanisms preventing 
adequate functioning. One mechanism is active transport to remove the substance, also 
known as resistance. A superfamily of multidrug resistance proteins, belonging to the ATP-
binding cassette transporters, drives substances away by an ATP-dependent process 
(Palmer, 2010). One of the most abundant proteins is the P-glycoprotein. This mechanism is 
responsible for the failure of some anticancer drugs. Another family of egress transporters is 
the organic anion transporting proteins. 
In the field of HD, efforts are ongoing to deliver innovative drugs to the brain via the 
systemic route and drugs are designed to use one of the three mechanisms to cross the BBB, 
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as explained earlier. For instance, Lee and associates described the use of a peptide nucleic 
acid as an antisense which was able to access endogenous transferrin transport pathways 
(receptor mediated endocytosis) and reach the brain in a transgenic mouse model (Lee et al., 
2002). However, there are also efforts to bypass the BBB, and to deliver the drug using either 
the ventricle system or intraparenchymally. 
7. Conclusion 
To date there is no treatment to prevent or even slow down the progression of HD. 
Considerable research has been performed to gain more insight into HD pathology. Next to 
the well-known toxic gain of polyQ protein function, loss of wild-type function and a toxic 
gain of expanded CAG repeat RNA was also suggested recently, and needs to be examined 
in more detail. 
Recent results using SNP specific siRNAs and CAG targeting AONs look promising both in 
vitro and in vivo. To develop an effective HD therapy, it is likely that a combination of 
different RNA modifying approaches will be optimal to lower mutant htt levels. Extensive 
research is required to rule out toxic off-targets effects and elucidate the exact mode of 
action of these RNA modulating therapeutics. Ongoing clinical trials for other 
neurodegenerative disorders, such as in ALS, will give us more insights in the potential of 
RNA modulating therapeutics. 
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